Investment Analysts’ Recent Ratings Updates for STAAR Surgical (STAA)

STAAR Surgical (NASDAQ: STAA) has recently received a number of price target changes and ratings updates:

• 1/28/2026 – STAAR Surgical had its price target lowered by analysts at Jefferies Financial Group Inc. from $28.00 to $21.50. They now have a “buy” rating on the stock.
• 1/22/2026 – STAAR Surgical had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 1/16/2026 – STAAR Surgical is now covered by analysts at Morgan Stanley. They set an “underweight” rating and a $13.00 price target on the stock.
• 1/15/2026 – STAAR Surgical had its price target lowered by analysts at Canaccord Genuity Group Inc. from $30.75 to $22.00. They now have a “hold” rating on the stock.
• 1/6/2026 – STAAR Surgical had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 1/6/2026 – STAAR Surgical had its “neutral” rating reaffirmed by analysts at BTIG Research.
• 12/10/2025 – STAAR Surgical had its price target raised by analysts at Wells Fargo & Company from $28.00 to $30.75. They now have an “equal weight” rating on the stock.
• 12/9/2025 – STAAR Surgical had its price target raised by analysts at Canaccord Genuity Group Inc. from $28.00 to $30.75. They now have a “hold” rating on the stock.

Insider Activity

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. purchased 27,485 shares of the stock in a transaction that occurred on Friday, January 9th. The stock was purchased at an average cost of $22.05 per share, with a total value of $606,044.25. Following the completion of the acquisition, the insider directly owned 15,453,629 shares of the company’s stock, valued at $340,752,519.45. This trade represents a 0.18% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders have acquired 1,934,138 shares of company stock worth $50,485,791. 0.59% of the stock is currently owned by insiders.

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.